Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services
Prescription Drugs
Reports
Displaying 41 - 50 of 85. 10 per page. Page 5.
Advanced SearchASPE Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services
Report to Congress
Report to Congress: Prescription Drug Pricing Report
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
Westat Printer Friendly Version in PDF Format (3 PDF pages)
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case management.
Public Listing Status of Data-Waivered Providers: Data Brief
Printer Friendly Version in PDF Format (3 PDF pages)
ASPE Issue Brief
Assessing the Costs and Benefits of Extending Coverage of Immunosuppressive Drugs under Medicare
By statute, the majority of patients with end-stage renal disease (ESRD) are eligible for Medicare, regardless of age. Kidney transplantation is ultimately considered the best treatment for ESRD, but ESRD-related eligibility for Medicare coverage extends for only 36 months post-transplant.
Using Evidence to Drive Decision-Making in Government
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
State Policy Levers for Expanding Family-Centered Medication-Assisted Treatment
Printer Friendly Version in PDF Format (55 PDF pages)
ASPE Issue Brief
Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief
Printer Friendly Version in PDF Format (5 PDF pages)